Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand London, UK – June 15, 2026 Stablepharma Limited, specialists in thermostable formulations, today announced the signing of a Letter of Intent (LOI) with AFT Pharmaceuticals (NZX: AFT; ASX: AFP) regarding the proposed distribution of SPVX02, their lead fridge-free […]
Read More
London, UK – 15 January 2026 – Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation […]
Read More